CMIC will work to advance decentralized trials in Japan.
CMIC, a Japanese contract resource organization (CRO), announced on Jan. 12, 2021 that it has joined the Decentralized Trials and Research Alliance (DTRA), an organization aiming to accelerate the adoption of decentralized clinical trials, as a founding company.
By joining as a founding company, CMIC will become a part of the DTRA Leadership Council and will begin advancing decentralized trials in Japan by establishing its connection with organizations and companies in the United States, CMIC said in a company press release.
“By joining the Leadership Council, CMIC will be able to study real-world examples of decentralized clinical trials that are led in the US, and network with US organizations,” said Toru Fujieda, president of CMIC, in the press release. “Through this, CMIC will be able to formulate realistic and efficient studies within the Japanese clinical trial environment and propose solutions for challenges that arise during a trial. As a member of DTRA, we will leverage the latest global digital health technology to the fullest and contribute to smooth decentralized trial conduct in Japan. Furthermore, as the largest Japanese CRO with a broad Asian footprint, we will bring our decentralized trial adoption experiences, trends, and needs of the fast-growing Asian market into DTRA, in order to facilitate the development of future global standards.”
Source: CMIC
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.